Therefore, the ability of NB3F18 to bind to glioblastoma stem cells to a greater extent than to the rest of the analyzed cells and the formation of a moderate affinity complex between NB3F18 and FREM2 are consistent with the purpose of our research to develop a molecular tool able to target a specific subset of glioblastoma cells. The gene discussed is FREM2; the disease is glioblastoma.